- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Fourth Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Carnitor | Leadiant | levocarnitine | Hikma | Used for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. It is also indicated to prevent and treat carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. | 10/5/2023 |
Mydayis | Takeda | amphetamine / dextroamphetamine | Teva | Used to treat attention deficit hyperactivity disorder (ADHD) in patients 13 years and older. | 10/10/2023 |
Jadenu Sprinkle | Novartis | deferasirox | Camber | Used to treat chronic iron overload (1) due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, and (2) in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes exhibiting elevated liver and serum iron concentrations. | 10/12/2023 |
Azopt | Novartis | brinzolamide | Padagis | Used to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers. | 10/13/2023 |
Prezista | Johnson & Johnson | darunavir | Camber | Used to treat HIV-1 infection in adult and pediatric patients 3 years of age and older. | 10/18/2023 |
Tranexamic Acid Sodium Chloride Injection | Exela | tranexamic acid | Amneal | Used for heavy menstrual bleeding and short-term prevention in patients with hemophilia; this includes tooth extractions in patients with hemophilia as well as menorrhagia in these patients. | 10/19/2023 |
Votrient | Novartis | pazopanib | Apotex | Used to treat adults with advanced renal cell carcinoma (RCC). | 10/20/2023 |
Afinitor | Novartis | everolimus | Teva | Used to treat patients with advanced hormone receptor—positive, HER2-negative breast cancer in postmenopausal women; advanced renal cell carcinoma; progressive neuroendocrine tumors (NETs) of pancreatic origin; and progressive, well-differentiated, non-functional NETs of gastrointestinal or lung origin that are unresectable; and renal angiomyolipoma and tuberous sclerosis complex. | 10/23/2023 |
Inspra | Pfizer | eplerenone | Camber | Used to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction and for the treatment of hypertension, to lower blood pressure. | 10/25/2023 |
Calcium Gluconate | Fresenius Kabi | calcium gluconate | Somerset | Used to treat acute symptomatic hypocalcemia in pediatric and adult patients. | 10/27/2023 |
Diastat AcuDial | Bausch Health | diazepam | Novel Laboratories (Lupin) | Used to control seizures (eg, seizure clusters, acute repetitive seizures) in patients who have epilepsy. | 11/2/2023 |
Mitigare | Hikma | colchicine | Par | Used for prophylaxis of gout flares in adults. | 11/2/2023 |
Livalo | Kowa | pitavastatin | Teva | Used to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia. | 11/2/2023 |
Livalo | Kowa | pitavastatin | Upsher-Smith Labs | Used to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia. | 11/6/2023 |
Zemuron | Organon | rocuronium bromide | Caplin Steriles (Lupin) |
Used for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. | 11/8/2023 |
Jadenu Sprinkle | Novartis | deferasirox | Teva | Used to treat chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. | 11/10/2023 |
Locoid | Bausch Health | hydrocortisone butyrate | J. Molner | Used to treat symptoms of dermatoses. | 11/15/2023 |
Forteo | Eli Lilly | teriparatide | Teva | Used to treat osteoporosis. | 11/17/2023 |
Forteo | Eli Lilly | teriparatide | Apotex | Used to treat osteoporosis. | 11/21/2023 |
Pepcid | Johnson & Johnson | famotidine | Camber | Used to treat active duodenal ulcer, active gastric ulcer, GERD, erosive esophagitis due to GERD, treatment of pathological hypersecretory conditions, reduction of the rusk of DU recurrence in adults. Used to treat peptic ulcer disease, GERD in pediatric patients 1 year or older. Used to treat GERD for pediatric patients less than 1 year of age. | 11/27/2023 |
Vascepa | Amarin | icosapent | Amneal / Strides | Used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. | 12/1/2023 |
Turqoz | Wyeth | norgestrel / ethinyl estradiol | Lupin | Used to prevent pregnancy. | 12/1/2023 |
Dexamethasone | Hikma | dexamethasone | Apotex | Used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin conditions, and flare-ups of multiple sclerosis. | 12/12/2023 |
Vidaza | Bristol-Myers Squibb | azacitidine | Apotex | Used for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy. | 12/13/2023 |
Cetrotide | Merck Serono | cetrorelix | Teva | Used to prevent premature ovulation (early release of eggs from the ovary). It is given to women having ovarian stimulation (fertility treatment where the ovaries are stimulated to produce more eggs). | 12/14/2023 |
Immphentiv | Hikma | phenylephrine | Hikma | Used to increase blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. | 12/19/2023 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.